Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Mario Cazzola, Nicola A Hanania, Clive P Page & Maria Gabriella Matera. (2023) Novel Anti-Inflammatory Approaches to COPD. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 1333-1352.
Read now
Read now
Luigino Calzetta, Beatrice Ludovica Ritondo, Maria Gabriella Matera, Alfredo Chetta & Paola Rogliani. (2022) Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies. Expert Review of Respiratory Medicine 16:3, pages 357-365.
Read now
Read now
Maria Gabriella Matera, Luigino Calzetta, Rosa Annibale, Francesco Russo & Mario Cazzola. (2021) Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Review of Clinical Pharmacology 14:8, pages 1015-1027.
Read now
Read now
Luigino Calzetta, Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2020) The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology 13:8, pages 865-874.
Read now
Read now
Ijeoma M Muo, Sandra D MacDonald, Ritu Madan, Sung-Jun Park, Ahmed M Gharib, Pedro E Martinez, Mary F Walter, Shanna B Yang, Justin A Rodante, Amber B Courville, Peter J Walter, Hongyi Cai, Michael Glicksman, Gioia M Guerrieri, Rivka R Ben-Dor, Ronald Ouwerkerk, Stephanie Mao & Jay H Chung. (2019) Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study. Diabetes, Metabolic Syndrome and Obesity 12, pages 743-759.
Read now
Read now
Mario Cazzola, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2019) Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of
COPD. Expert Opinion on Investigational Drugs 28:10, pages 827-833.
Read now
Read now
Paola Rogliani, Vito Brusasco, Leonardo Fabbri, Andrea Ungar, Elisa Muscianisi, Ilaria Barisone, Alberto Corsini & Giuseppe De Angelis. (2018) Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 12:2, pages 103-112.
Read now
Read now
Mario Cazzola, Paola Rogliani, Ermanno Puxeddu, Josuel Ora & Maria Gabriella Matera. (2018) An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine 12:1, pages 43-54.
Read now
Read now
Uwe Wollina. (2017) Emerging treatments for pyoderma gangrenosum. Expert Opinion on Orphan Drugs 5:10, pages 827-832.
Read now
Read now
Paola Rogliani, Maria Gabriella Matera, Josuel Ora, Mario Cazzola & Luigino Calzetta. (2017) The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3469-3485.
Read now
Read now
Articles from other publishers (33)
Mirco Govoni, Michele BassiDebora SantoroSinéad Donegan & Dave Singh. (2023) Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 208:5, pages 559-569.
Crossref
Crossref
M. Mansilla-Polo, E. Gimeno & D. Morgado-Carrasco. (2023) Roflumilast tópico y oral en dermatología. Una revisión narrativa. Actas Dermo-Sifiliográficas.
Crossref
Crossref
Feng Zhou, Yue Huang, Lu Liu, Zhendong Song, Ke-Qiang Hou, Yifan Yang, Hai-Bin Luo, Yi-You Huang & Xiao-Feng Xiong. (2022) Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects. Biochemical Pharmacology 202, pages 115123.
Crossref
Crossref
Zhendong Song, Yi-You Huang, Ke-Qiang Hou, Lu Liu, Feng Zhou, Yue Huang, Guohui Wan, Hai-Bin Luo & Xiao-Feng Xiong. (2022) Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. Journal of Medicinal Chemistry 65:5, pages 4238-4254.
Crossref
Crossref
Sumbal Naseem, Muhammad Hassan, Shazia Nasim Akhtar, Fibhaa Syed, Naveed Ullah Khan & Muhammad Usman. (2022) Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Cureus.
Crossref
Crossref
Hoang Oanh Nguyen, Tiziana Schioppa, Laura Tiberio, Fabrizio Facchinetti, Gino Villetti, Maurizio Civelli, Annalisa Del Prete, Francesca Sozio, Carolina Gaudenzi, Mauro Passari, Ilaria Barbazza, Silvano Sozzani, Valentina Salvi & Daniela Bosisio. (2022) The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs. Frontiers in Immunology 12.
Crossref
Crossref
Bruno Sposato, Elisa Petrucci, Andrea Serafini, Fabio Lena, Leonardo Gianluca Lacerenza, Andrea Montagnani, Massimo Alessandri, Alberto Cresti, Raffaele Scala, Paola Rogliani, Alberto Ricci, Antonio Perrella & Marco Scalese. (2021) Which LABA/LAMA should be chosen in COPD patients in real life?. Pulmonary Pharmacology & Therapeutics 71, pages 102076.
Crossref
Crossref
Anne E. Dixon, Kathryn V. Blake, Emily A. DiMango, Mark T. Dransfield, Laura C. Feemster, Olivia Johnson, Gem Roy, Heather Hazucha, Jean Harvey, Meredith C. McCormack, Robert A. Wise & Janet T. Holbrook. (2021) The challenge of addressing obesity in people with poorly controlled asthma. Obesity Science & Practice 7:6, pages 682-689.
Crossref
Crossref
Fabrizio Facchinetti, Maurizio Civelli, Dave Singh, Alberto Papi, Aida Emirova & Mirco Govoni. (2021) Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Frontiers in Pharmacology 12.
Crossref
Crossref
Suyun Yu, Caili Zhang, Zhijun Yan, Qingqing Fang & Xiwen Gao. (2021) Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. Computational and Mathematical Methods in Medicine 2021, pages 1-6.
Crossref
Crossref
Priyanka Saroj, Yashika Bansal, Raghunath Singh, Ansab Akhtar, Rupinder Kaur Sodhi, Mahendra Bishnoi, Sangeeta Pilkhwal Sah & Anurag Kuhad. (2021) Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington’s disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway. Inflammopharmacology 29:2, pages 499-511.
Crossref
Crossref
Chunyuan Zhang, Zeting Xing, Meiyun Tan, Yanwen Wu & Wei Zeng. (2021)
Roflumilast Ameliorates Isoflurane-Induced Inflammation in Astrocytes
via
the CREB/BDNF Signaling Pathway
. ACS Omega 6:6, pages 4167-4174.
Crossref
Crossref
Agnieszka Król, Robert Palmér, Virginie Rondeau, Stephen Rennard, Ulf G. Eriksson & Alexandra Jauhiainen. (2020) Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials. Respiratory Research 21:1.
Crossref
Crossref
Manar Mohammed El Tabaa & Maram Mohammed El Tabaa. (2020) New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19. European Journal of Pharmacology 889, pages 173615.
Crossref
Crossref
O. V. Zhukova & A. L. Khokhlov. (2020) Analysis of the long-term effectiveness of a drug in the treatment of a chronic disease is the basis of rational pharmacotherapy (on the example of the use of roflumilast in the treatment of chronic obstructive pulmonary disease). Kachestvennaya klinicheskaya praktika:3, pages 35-39.
Crossref
Crossref
Lal Jabaris S Sugin, Arumugam Murugesan, Menon Bindu & K Narayan Sunil. (2020) Roflumilast: A potential drug for the treatment of cognitive impairment?. Neuroscience Letters 736, pages 135281.
Crossref
Crossref
Roberta Fusco, Rosanna Di Paola, Salvatore Cuzzocrea, Maria Gabriella Matera & Clive Page. 2020. Cardiovascular Complications of Respiratory Disorders. Cardiovascular Complications of Respiratory Disorders
279
286
.
Huang-Ping Yu, Fu-Chao Liu, Cheng-Yu Lin, Ani Umoro, Jiří Trousil, Tsong-Long Hwang & Jia-You Fang. (2020) Suppression of neutrophilic inflammation can be modulated by the droplet size of anti-inflammatory nanoemulsions. Nanomedicine 15:8, pages 773-791.
Crossref
Crossref
Simon Lea, Alexandra Metryka, Jian Li, Andrew Higham, Charles Bridgewood, Gino Villetti, Maurizio Civelli, Fabrizio Facchinetti & Dave Singh. (2019) The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine 123, pages 154739.
Crossref
Crossref
Yixian Liao, Xiuhua Jia, Yongmei Tang, Sumei Li, Yipeng Zang, Lei Wang, Zi-Ning Cui & Gaopeng Song. (2019) Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification. Bioorganic & Medicinal Chemistry Letters 29:22, pages 126720.
Crossref
Crossref
Paola Rogliani & Luigino Calzetta. (2019) Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials. AboutOpen 5:1, pages 55-61.
Crossref
Crossref
Simon Lea, Alexandra Metryka, Jian Li, Andrew Higham, Charles Bridgewood, Gino Villetti, Maurizio Civelli, Fabrizio Facchinetti & Dave Singh. (2019) WITHDRAWN: The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine: X, pages 100006.
Crossref
Crossref
Priscila Baltazar Gonçalves & Nelilma Correia Romeiro. (2019) Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD). European Journal of Medicinal Chemistry 163, pages 911-931.
Crossref
Crossref
Mario Cazzola, Paola Rogliani, Daiana Stolz & Maria Gabriella Matera. (2019) Pharmacological treatment and current controversies in COPD. F1000Research 8, pages 1533.
Crossref
Crossref
Thomas Southworth, Manminder Kaur, Lynsey Hodgson, Fabrizio Facchinetti, Gino Villetti, Maurizio Civelli & Dave Singh. (2019) Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. Cytokine 113, pages 68-73.
Crossref
Crossref
Heng Li, Jianping Zuo & Wei Tang. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology 9.
Crossref
Crossref
Øyvind Nicolay Ulland Salvesen, Jesper Rømhild Davidsen, Anton Pottegård & Daniel Pilsgaard Henriksen. (2018) Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study. Basic & Clinical Pharmacology & Toxicology 123:3, pages 314-319.
Crossref
Crossref
Hyonsoo Joo, Deokjae HanJae Ha LeeChin Kook Rhee. (2018) Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study. Tuberculosis and Respiratory Diseases 81:4, pages 299.
Crossref
Crossref
Shipeng Gong, Yongning Chen, Fanliang Meng, Yadi Zhang, Huan Wu & Fei Wu. (2017) Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer. Oncotarget 8:68, pages 112341-112353.
Crossref
Crossref
L. Calzetta, P. Roncada, D. di Cave, L. Bonizzi, A. Urbani, E. Pistocchini, P. Rogliani & M. G. Matera. (2017) Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis. Equine Veterinary Journal 49:6, pages 710-717.
Crossref
Crossref
Mónica Gómez-Rodríguez & Rafael Golpe. (2017) Intolerance to roflumilast in real-life clinical practice. European Journal of Internal Medicine 43, pages e28-e29.
Crossref
Crossref
Mario Cazzola, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2017) The Challenges of Precision Medicine in COPD. Molecular Diagnosis & Therapy 21:4, pages 345-355.
Crossref
Crossref
Luigino Calzetta, Paola Rogliani, Josuel Ora, Ermanno Puxeddu, Mario Cazzola & Maria Gabriella Matera. (2017) LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review 26:143, pages 160043.
Crossref
Crossref